Role of rifaximin in the management of alcohol-associated hepatitis: a systematic review and meta-analysis.

Zohaib AhmedJoyce BadalMohamad NawrasDhanushya BattepatiUmer FarooqSyeda Faiza ArifWade Lee-SmithMuhammad AzizUmair IqbalAhmad NawazManesh Kumar GangwaniAmna IqbalAbdallah KobeissyBenyam D AddissieMona HassanSammy Saab

Published in: Journal of gastroenterology and hepatology (2023)

The use of rifaximin in AAH is associated with a lower rate of infection rate than the non-rifaximin group. Additional research is needed to determine whether this effect is more pronounced in patients concurrently being treated with prednisolone. Differences in 90-day or overall mortality did not reach statistical significance. Further studies, particularly large randomized controlled trials, are needed to establish the role of rifaximin in AAH, especially as an adjunct therapy with prednisolone.

Keyphrases

irritable bowel syndrome
newly diagnosed
randomized controlled trial
end stage renal disease
ejection fraction
cardiovascular events
type diabetes
systematic review
coronary artery disease
patient reported outcomes
bone marrow
mesenchymal stem cells